GlycoMimetics, Inc. Expected to Post FY2026 Earnings of $0.14 Per Share (NASDAQ:GLYC)

GlycoMimetics, Inc. (NASDAQ:GLYC) – Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for GlycoMimetics in a note issued to investors on Wednesday, March 27th. HC Wainwright analyst E. White anticipates that the biotechnology company will post earnings of $0.14 per share for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for GlycoMimetics’ current full-year earnings is ($0.60) per share.

Several other brokerages have also commented on GLYC. Capital One Financial reaffirmed an “overweight” rating on shares of GlycoMimetics in a report on Thursday, February 22nd. StockNews.com lowered GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, March 14th.

GlycoMimetics Price Performance

GLYC stock opened at $3.18 on Thursday. GlycoMimetics has a 1-year low of $1.11 and a 1-year high of $3.53. The stock has a market capitalization of $204.95 million, a P/E ratio of -5.05 and a beta of 2.19. The business has a fifty day moving average price of $3.00 and a 200-day moving average price of $2.18.

Hedge Funds Weigh In On GlycoMimetics

Several large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. purchased a new stake in shares of GlycoMimetics in the fourth quarter worth about $68,000. Tower Research Capital LLC TRC bought a new position in shares of GlycoMimetics during the first quarter valued at approximately $30,000. Jane Street Group LLC bought a new position in shares of GlycoMimetics during the fourth quarter valued at approximately $75,000. Acuta Capital Partners LLC bought a new position in shares of GlycoMimetics during the third quarter valued at approximately $41,000. Finally, XTX Topco Ltd bought a new position in shares of GlycoMimetics during the second quarter valued at approximately $52,000. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.